Sublingual Immunotherapy in Mite-sensitized Patients with Atopic Dermatitis: a Randomized Controlled Study

Overview

Journal Postepy Dermatol Alergol

Publisher Termedia

Specialty Allergy & Immunology

Date 2021 Aug 19

PMID 34408569

Citations 6

Authors

Nansheng Yu

Hongyu Luo

Donglong Liang

Na Lu

Affiliations

Soon will be listed here.

Abstract

Introduction: Sublingual immunotherapy (SLIT) has been shown to be efficacious in patients with airway allergic diseases. However, less data have been demonstrated to show the efficacy of SLIT in patients with atopic dermatitis (AD).

Aim: This study is to evaluate, in a randomized controlled study, the effect of SLIT with house dust mite (HDM) in patients with mild-moderate AD.

Material And Methods: AD patients aged 4 to 60 years with a Scoring Atopic Dermatitis (SCORAD) score of 7-40 and sensitization to HDM were enrolled in the study. SLIT or control treatment was given for 24 months. SCORAD, visual analog scale (VAS) score were recorded at 6, 12, 24 month, and rescue medications were required to be recorded in the diary card. A serum level of specific IgE was tested at 24-month treatment.

Results: Ninety-six patients were enrolled, and forty-eight were allocated to SLIT. Thirty-nine patients in the SLIT group and thirty-eight patients in the control group completed the study. The patients in the SLIT group had significantly decreased ΔSCORAD, VAS and rescue medication score from 12 months' treatment compared with the control group ( < 0.05). At 24 months of treatment, no significant change of specific IgE ( < 0.05) was observed in both groups. No severe adverse events were reported during the treatment.

Conclusions: Two years' SLIT to HDM significantly improved the clinical symptoms and reduced drug use in patients with mild-moderate AD. SLIT may represent an additional therapeutic tool for the treatment of AD in properly selected patients.

Citing Articles

Effect of house dust mite sublingual immunotherapy in patients with adult atopic dermatitis with rhinitis.

Mizuno M, Imamura S, Yoshioka A, Washio K, Oda Y, Matsuhara H Future Sci OA. 2024; 10(1):2419779.

PMID: 39539183 PMC: 11572311. DOI: 10.1080/20565623.2024.2419779.

Advancements in Allergen Immunotherapy for the Treatment of Atopic Dermatitis.

Guo B, Wu K, Chen C, Lin W, Chang Y, Lin M Int J Mol Sci. 2024; 25(2).

PMID: 38279315 PMC: 10816003. DOI: 10.3390/ijms25021316.

KAAACI Guidelines for Allergen Immunotherapy.

Lee H, Lee S, Kang S, Kim K, Kim J, Ryu G Allergy Asthma Immunol Res. 2023; 15(6):725-756.

PMID: 37957792 PMC: 10643862. DOI: 10.4168/aair.2023.15.6.725.

A concept for integrated care pathways for atopic dermatitis-A GA LEN ADCARE initiative.

Zuberbier T, Abdul Latiff A, Aggelidis X, Augustin M, Balan R, Bangert C Clin Transl Allergy. 2023; 13(9):e12299.

PMID: 37746794 PMC: 10500634. DOI: 10.1002/clt2.12299.

Is there room for allergen immunotherapy for the treatment of atopic dermatitis in the precision medicine era?.

Pessina B, Giovannini M, Mori F, Di Cara G, Novembre E, Chan S Front Pediatr. 2022; 10:1050560.

PMID: 36405820 PMC: 9666735. DOI: 10.3389/fped.2022.1050560.

References

Till S, Francis J, Nouri-Aria K, Durham S . Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004; 113(6):1025-34. DOI: 10.1016/j.jaci.2004.03.024. View

Pajno G, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F . Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007; 120(1):164-70. DOI: 10.1016/j.jaci.2007.04.008. View

Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M . Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006; 61(2):202-5. DOI: 10.1111/j.1398-9995.2006.00974.x. View

Cadario G, Galluccio A, Pezza M, Appino A, Milani M, Pecora S . Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr Med Res Opin. 2007; 23(10):2503-6. DOI: 10.1185/030079907X226096. View

Wang D, Chen L, Cheng L, Li K, Yuan H, Lu J . Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial. Laryngoscope. 2013; 123(6):1334-40. DOI: 10.1002/lary.23935. View

Di Rienzo V, Cadario G, Grieco T, Galluccio A, Caffarelli C, Liotta G . Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study. Ann Allergy Asthma Immunol. 2014; 113(6):671-673.e1. DOI: 10.1016/j.anai.2014.09.009. View

Schram M, Tedja A, Spijker R, Bos J, Williams H, Spuls P . Is there a rural/urban gradient in the prevalence of eczema? A systematic review. Br J Dermatol. 2010; 162(5):964-73. DOI: 10.1111/j.1365-2133.2010.09689.x. View

Cork M, Robinson D, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A . New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol. 2006; 118(1):3-21. DOI: 10.1016/j.jaci.2006.04.042. View

Scalabrin D, Bavbek S, Perzanowski M, Wilson B, Platts-Mills T, Wheatley L . Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. J Allergy Clin Immunol. 1999; 104(6):1273-9. DOI: 10.1016/s0091-6749(99)70024-2. View

10.

You H, Yang M, Kim G, Cho H, Kim W, Mun J . Effectiveness of Specific Sublingual Immunotherapy in Korean Patients with Atopic Dermatitis. Ann Dermatol. 2017; 29(1):1-5. PMC: 5318503. DOI: 10.5021/ad.2017.29.1.1. View

11.

Nahm D, Kim M . Treatment of severe atopic dermatitis with a combination of subcutaneous allergen immunotherapy and cyclosporin. Yonsei Med J. 2011; 53(1):158-63. PMC: 3250339. DOI: 10.3349/ymj.2012.53.1.158. View

12.

Gomez Vera J, Flores Sandoval G, Orea Solano M, Lopez Tiro J, Jimenez Saab N . [Safety and efficacy of specific sublingual immunotherapy in patients with asthma and allergy to Dermatophagoides pteronyssinus]. Rev Alerg Mex. 2006; 52(6):231-6. View

13.

Asher M, Montefort S, Bjorksten B, Lai C, Strachan D, Weiland S . Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006; 368(9537):733-43. DOI: 10.1016/S0140-6736(06)69283-0. View

14.

. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993; 186(1):23-31. DOI: 10.1159/000247298. View

15.

Durham S . Tradition and innovation: finding the right balance. J Allergy Clin Immunol. 2007; 119(4):792-5. DOI: 10.1016/j.jaci.2007.02.034. View

16.

Grim Hostetler S, Kaffenberger B, Hostetler T, Zirwas M . The role of airborne proteins in atopic dermatitis. J Clin Aesthet Dermatol. 2010; 3(1):22-31. PMC: 2921737. View

17.

Cox L, Linnemann D, Nolte H, Weldon D, Finegold I, Nelson H . Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006; 117(5):1021-35. DOI: 10.1016/j.jaci.2006.02.040. View

18.

Johansson S, Bieber T, Dahl R, Friedmann P, Lanier B, Lockey R . Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004; 113(5):832-6. DOI: 10.1016/j.jaci.2003.12.591. View

19.

Novak N . Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol. 2007; 7(6):542-46. DOI: 10.1097/ACI.0b013e3282f1d66c. View

20.

Silny W, Czarnecka-Operacz M . [Specific immunotherapy in the treatment of patients with atopic dermatitis--results of double blind placebo controlled study]. Pol Merkur Lekarski. 2007; 21(126):558-65. View